Herman Burger
Rotterdam, ZH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trial.
Journal: European journal of cancer (Oxford, England : 1990)
Published: October 16, 2016
Loss of SLCO1B3 drives taxane resistance in prostate cancer.
Journal: British journal of cancer
Published: July 04, 2016
Understanding taxanes in prostate cancer; importance of intratumoral drug accumulation.
Journal: The Prostate
Published: November 26, 2015
Circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients.
Journal: Breast cancer research and treatment
Published: February 24, 2015
Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence.
Journal: Clinical pharmacokinetics
Published: February 04, 2015
Lysosomal Sequestration Determines Intracellular Imatinib Levels.
Journal: Molecular pharmacology
Published: December 16, 2014
Phase I study of RGB-286638, a novel, multitargeted cyclin-dependent kinase inhibitor in patients with solid tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 16, 2014
Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 29, 2013
Can "specific" OCT1 inhibitors be used to determine OCT1 transporter activity toward imatinib?
Journal: Blood
Published: June 15, 2013
A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors.
Journal: Investigational new drugs
Published: July 27, 2012
Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 07, 2011
Showing 1-11 of 11
Last Updated: 09/26/2026